

April 19, 2024-

## Kyoto Drug Discovery & Development Doses First Subject in its US Phase 2 Trial of KUS121 in Central Retinal Artery Occlusion (CRAO)

Kyoto Drug Discovery & Development Co., Ltd., a clinical-stage pharmaceutical company specializing in innovative neuroprotectant therapies, announced today the dosing of the first subject in its Phase 2 GION study. This study aims to assess the efficacy and safety of KUS121 in patients with central retinal artery occlusion (CRAO) at multiple research facilities across the U.S.

Details about the study can be found at: <https://clinicaltrials.gov/study/NCT06178055>.

### ▼Contacts for inquiries:

#### Investors and Media

Kyoto Drug Discovery & Development Investor Relations  
[info@kyoto-drug.com](mailto:info@kyoto-drug.com)

#### Clinical Trials

Kyoto Drug Discovery & Development Clinical Trials Contact  
[clinical@kyoto-drug.com](mailto:clinical@kyoto-drug.com)